UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, DC D.C. 20549

FORM 8-K

CURRENT ~~REPORT~~ ~~PURSUANT~~REPORT

~~TO SECTION~~Pursuant to Section 13 ORor 15(Dd) OFof ~~THE~~the Securities and Exchange Act of 1934

~~SECURITIES EXCHANGE~~Date ~~ACT~~of OFReport ~~1934~~(date of earliest event reported): November 16, 2023

Date of report (Date of earliest event reported): October 2, 2023

Tengjun Biotechnology Corp.

(Exact name of registrant as specified in its charter)

Nevada	333-169397	27-3042462
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(IRS Employer Identification No.)
(State or other jurisdiction	(Commission File Number)	(I.R.S. Employer
of incorporation)		Identification Number)

East Jinze Road and South Huimin Road, Food Industry Economic and Technology Development District,

Jinxiang County, Jining City, Shandong Province, China

(Address of ~~Principal~~principal ~~Executive~~executive ~~Offices~~offices and zip code)

(86) 0537-8711599 ~~(Registrant’s Telephone Number, Including Area Code)~~

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered:
None		None		None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 4 5.0102 ~~CHANGES~~Departure INof ~~REGISTRANT’S CERTIFYING~~Directors ~~ACCOUNTANT~~or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~On October~~Effective 2,as of November 16, 2023, ~~Tengjun~~Ruiming ~~Biotechnology~~Zhou ~~Corp.,~~resigned afrom ~~company~~his ~~incorporated~~position ~~under~~as ~~the~~a ~~laws~~member of the ~~State~~Board of ~~Nevada~~Directors (the “~~Company~~Board”), ~~elected~~ ~~not~~the toCEO ~~continue~~and ~~the~~CFO ~~engagement~~ of ~~PWN~~Tengjun Biotechnology ~~LLP~~Corp ~~serving as~~ (the “Company”). Mr. Zhou’s ~~independent~~resignation ~~registered~~was ~~public~~not ~~accounting~~a ~~firm.~~result ~~The termination~~ of ~~the~~any ~~engagement~~disagreements ofwith ~~PWN~~the ~~LLP~~Company ~~has~~on any ~~been~~matter ~~approved~~relating byto ~~the~~its ~~Board~~operations, ofpolicies ~~Directors~~or ~~of the Company (the “Board”)~~practices.

~~The report~~Effective as of ~~PWN~~November ~~LLP~~16, 2023, on the ~~financial~~Board ~~statements~~appointed ofQingbao ~~the~~Wang ~~Company~~ as a member of ~~and~~the ~~for~~Board, the ~~fiscal~~CEO ~~year~~and ~~ended~~CFO ~~December~~of 31the Company, ~~2022~~until ~~did~~the ~~not~~next ~~contain~~annual ~~any~~meeting of the ~~adverse~~Company’s ~~opinion~~stockholders, orand ~~disclaimer~~until ofhis ~~opinion~~successor ~~and~~is ~~was~~elected ~~not~~and qualified or ~~modified~~until ashis toprior ~~uncertainty~~death, ~~audit~~resignation ~~scope~~ or ~~accounting principles~~removal.

~~During~~Mr. Qingbao ~~the~~Wang, ~~Company’s~~age ~~two~~49, ~~most~~has ~~recent~~been ~~fiscal years~~served ~~and~~as ~~the~~a ~~subsequent~~director ~~interim~~of ~~period~~Shandong ~~through~~Hawei ~~October~~Food 2Co., ~~2023,~~Ltd ~~there~~since ~~were~~June ~~disagreements~~2000. ~~with~~He ~~PWN~~graduated ~~LLP~~from ~~regarding~~Shaanxi ~~certain accounting treatments.~~University ~~Due to the provision~~ of ~~incorrect~~Finance ~~accounting information by the Company, PWN LLP discovered significant discrepancies~~ and ~~inconsistencies in~~Economics ~~the~~with ~~data~~a ~~when~~technical ~~reviewing~~secondary ~~the~~school ~~Company’s~~degree. ~~second~~Mr. ~~quarter~~Wang ~~financial~~is ~~statements.~~not As a ~~result,~~party ~~PWN LLP declined~~ to ~~recognize~~ any ~~revenue as~~transaction ofwith ~~June 30, 2023. On August 5, 2023, PWN LLP further notified~~ the Company that ~~action should be taken to prevent future reliance on~~would ~~the~~require ~~Company’s~~disclosure ~~previously~~under ~~issued~~Item ~~financial~~404(a) ~~statements~~of ~~contained~~Regulation ~~in the Annual Report on Form 10~~S-K ~~for the fiscal year ended December 31~~, ~~2022.~~and ~~The~~there ~~errors~~are ~~included~~no ~~mistakes~~arrangements inor ~~accounting~~understandings ~~policies,~~between ~~accounting~~Mr. ~~estimates,~~Wang and any other persons ~~discrepancies,~~pursuant ~~all~~to of which ~~had~~he awas ~~significant impact.~~appointed ~~PWN~~as ~~LLP~~Director ~~requested that the Company retrospectively restate the financial statements~~ and ~~make~~executive ~~corrections.~~officer ~~However,~~of ~~PWN LLP could not reach an agreement with~~ the Company ~~regarding those issues~~. ~~On August 29, 2023, PWN LLP communicated significant deficiencies to the management.~~

The issue has not been resolved to PWN LLP’s satisfaction prior to its dismissal. The Company’s management has discussed the subject matter of the disagreement described above with PWN LLP. The Company has authorized PWN LLP to respond fully to the inquiries of a successor independent registered public accounting firm related to the disagreement described above.1

The Company has provided PWN LLP with a copy of the foregoing disclosure and requested PWN LLP to furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made therein. A copy of the letter from PWN LLP is enclosed as Exhibit 16.1 to this Current Report.SIGNATURES

~~In connection~~Pursuant ~~with~~to the ~~foregoing,~~requirements of the ~~Board~~Securities ~~approved~~Exchange ~~the~~Act ~~engagement~~ of KG1934, ~~CPA LLP~~ as amended, the ~~Company’s~~Registrant ~~new~~has ~~independent~~duly ~~registered~~caused ~~public accounting~~this ~~firm~~report ~~with~~to ~~effect~~be ~~from~~signed ~~October~~on 2,its ~~2023~~behalf by the undersigned hereunder duly authorized.

During the Company’s two most recent fiscal years and the subsequent interim period through October 2, 2023, neither the Company nor anyone on its behalf consulted with KG CPA LLP regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements (and neither a written report nor oral advice was provided that KG CPA LLP concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue); or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and its related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

Date: November 17, 2023

	Tengjun Biotechnology Corp.

	By:	/s/ Qingbao Wang
		Qingbao Wang
		Chief Executive Officer

~~Item 9.01. Financial Statements and Exhibits.~~2

(d) Exhibits.

The exhibit listed in the following Exhibit Index is filed as part of this Current Report on Form 8-K.

Exhibit No.		Description
16.1		Letter from PWN LLP regarding change in certifying accountant
104		Cover page interactive data file (embedded within the iXBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Tengjun Biotechnology Corp.
Date: October 10, 2023	By:	/s/ Ruiming Zhou
	Name:	Ruiming Zhou
	Title:	Chief Executive Officer

Filing Compare · Tengjun Biotechnology Corp.